Shares of Enzo Biochem have been flying over the past year due to increased demand for its clinical products, successful patent resolutions and new product introductions, says the company's president Barry Weiner. Enzo recently pocketed a multi-million dollar settlement from Affymetrix and Weiner expects the successful legal resolutions to continue without disrupting the ongoing business. Weiner also says the harsh winter weather hurt Enzo's clinical business in the first quarter as fewer patients braved the cold to go to the doctor, yet he expects that to normalize going forward.

More from Video

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Will Tesla CEO Elon Musk Really Pulverize the Haters?

Will Tesla CEO Elon Musk Really Pulverize the Haters?

Jim Cramer's Investing Rule #4: Buy Damaged Stocks, Not Damaged Companies

Jim Cramer's Investing Rule #4: Buy Damaged Stocks, Not Damaged Companies

Jim Cramer's Investing Rule #3: Don't Buy Stocks All at Once

Jim Cramer's Investing Rule #3: Don't Buy Stocks All at Once